Society guideline links: Guillain-Barré syndrome

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Immunizations in adults" and "Society guideline links: Immunizations in children and adolescents".)

International

●World Health Organization (WHO): Assessment and management of Guillain-Barré syndrome in the context of Zika virus infection – Interim guidance update (2016)

●WHO: Psychosocial support for pregnant women and for families with microcephaly and other neurological complications in the context of Zika virus – Interim guidance for health-care providers (2016)

United States

●American Academy of Neurology (AAN): Practice parameter – Immunotherapy for Guillain-Barré syndrome (2003, reaffirmed 2022)

Europe

●European Federation of Neurological Societies (EFNS): Guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases (2008)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Guideline on suspected neurological conditions – Recognition and referral (2019, updated 2023)

●Public Health England (PHE): Guidance on Zika virus and Guillain-Barré syndrome (2016, updated 2017)

Japan

●[In Japanese] Japanese Society of Neurology (JSN): Guillain-Barré syndrome, Fisher syndrome clinical practice guideline (2013)